M300 (T)/ AT0000819818 /
NAV2024-09-20 | Chg.+3.8900 | Type of yield | Investment Focus | Investment company |
---|---|---|---|---|
283.9200EUR | +1.39% | reinvestment | Equity Worldwide | LLB Invest KAG ▶ |
GlobeNewswire
04-08
Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist De...
GlobeNewswire
03-05
Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in ...
GlobeNewswire
02-20
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Devel...
GlobeNewswire
02-16
Rocket EV Showcasing Melitron EV Charger Solutions at 2024 Canadian International Auto Show
GlobeNewswire
02-12
GeoCue and CHC Navigation Join Forces to Unveil an Exclusive LiDAR Innovation with the New TrueView ...
GlobeNewswire
2023-11-15
ArcelorMittal S.A.: ArcelorMittal enters the additive manufacturing industry as a steel powder suppl...
Newsfile Corp
2022-08-17
AECA Solutions Is Using Drone Technology to Potentially Help Prevent Natural Disasters
GlobeNewswire
2018-07-26
Global Smart Augmented Reality (AR) Glasses Market 2015-2024: With Apple Not Yet in the Market, Andr...
GlobeNewswire
2018-05-24
Global Managed Security Services Markets 2015-2018 & 2022: Competitve Scenario, Service Launches, In...